Heart:每周打盹1-2次可降低心血管疾病风险!

2019-11-22 不详 网络

打盹对心血管疾病(CVD)的影响一直存在着争议,因为大部分的研究忽略了打盹的频率这一因素。本研究的目的旨在评估打盹的频率和平均打盹时间对致死性CVD和非致死性CVD的影响。本研究纳入分析了3462名无基础CVD的瑞士人,并通过自我报告的方式收集其打盹的频率和打盹时间,经过平均5.3年时间的随访,有155件致死和非致死性CVD事件发生。与不打盹的相比,每周打盹1-2次的发生CVD事件风险明显更低(H

打盹对心血管疾病(CVD)的影响一直存在着争议,因为大部分的研究忽略了打盹的频率这一因素。本研究的目的旨在评估打盹的频率和平均打盹时间对致死性CVD和非致死性CVD的影响。

本研究纳入分析了3462名无基础CVD的瑞士人,并通过自我报告的方式收集其打盹的频率和打盹时间,经过平均5.3年时间的随访,有155件致死和非致死性CVD事件发生。与不打盹的相比,每周打盹1-2次的发生CVD事件风险明显更低(HR 0.52, 95%CI 0.28-0.95)。在非调整模型中,每周打盹6-7次的发生CVD风险更高(1.67, 95%CI 1.10-2.55),但在调整后的分析模型中这种相关性消失(HR 0.89, 95%CI 0.58-1.38)。阻塞性睡眠呼吸暂停和白天过度困倦都没有改变这种风险的降低。另外,打盹的时间与CVD发生风险无明显相关性。

研究结果显示,每周打盹1-2次会明显降低心血管疾病风险,而更高频率的打盹和打盹时间与心血管疾病发生无明显相关性。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1357306, encodeId=a57e135e306d0, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Nov 24 04:51:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473210, encodeId=5a1214e321060, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Sun Nov 24 04:51:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498654, encodeId=b23a1498654ca, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sun Nov 24 04:51:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563173, encodeId=40ac15631e32a, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sun Nov 24 04:51:00 CST 2019, time=2019-11-24, status=1, ipAttribution=)]
    2019-11-24 zhaojie88
  2. [GetPortalCommentsPageByObjectIdResponse(id=1357306, encodeId=a57e135e306d0, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Nov 24 04:51:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473210, encodeId=5a1214e321060, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Sun Nov 24 04:51:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498654, encodeId=b23a1498654ca, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sun Nov 24 04:51:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563173, encodeId=40ac15631e32a, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sun Nov 24 04:51:00 CST 2019, time=2019-11-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1357306, encodeId=a57e135e306d0, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Nov 24 04:51:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473210, encodeId=5a1214e321060, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Sun Nov 24 04:51:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498654, encodeId=b23a1498654ca, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sun Nov 24 04:51:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563173, encodeId=40ac15631e32a, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sun Nov 24 04:51:00 CST 2019, time=2019-11-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1357306, encodeId=a57e135e306d0, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Nov 24 04:51:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473210, encodeId=5a1214e321060, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Sun Nov 24 04:51:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498654, encodeId=b23a1498654ca, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sun Nov 24 04:51:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563173, encodeId=40ac15631e32a, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sun Nov 24 04:51:00 CST 2019, time=2019-11-24, status=1, ipAttribution=)]
    2019-11-24 slcumt

相关资讯

JACC:罕见基因突变与心源性猝死相关

来自49个基因的罕见突变可以增加导致心源性猝死的4个重要危险因素的发生率:心肌病、冠心病、遗传性心律失常和主动脉病或主动脉夹层。本研究的目的旨在评估心源性猝死病例中罕见致病性变异的患病率,以及这种变异在无症状成人人群中的患病率和临床重要性。本研究纳入分析了600例成年起病的心源性猝死患者和600正常对照,并对其进行了全外显子测序分析,最终识别出了5178个基因突变,其中14个被认为是致病突变或可能

JACC:ST段抬高型心梗患者应该选哪种冠脉支架?

目前,对于接受经皮冠脉介入治疗(PCI)的ST段抬高型心梗(STEMI)患者,尚无特异有效的药物洗脱支架(DES)被证实优于其他支架。本次荟萃分析研究的目的旨在比较和评估不同冠脉支架在STEMI患者中的安全性和有效性。 本研究回顾分析了来自15个随访时间超过12个月临床研究的10979名PCI患者(男性占77.3%,平均年龄为60.7岁),主要终点事件是心源性死亡、再梗死和靶血管血运重建的复

JACC:外科瓣膜术后永久起搏器植入的危险因素研究

需要永久起搏器(PPM)的心脏瓣膜手术后传导障碍的危险因素尚不清楚。本研究的目的旨在探究二尖瓣或主动脉瓣外科术后PPM植入的时间和危险因素。本研究纳入分析了77882名接受了二尖瓣或主动脉瓣外科手术的患者,主要终点事件是术后1年内的PPM植入。其中,有63.8%的患者接受了主动脉瓣置换术(AVR),18.9%患者接受了二尖瓣置换术(MVR),10.5%的患者接受了二尖瓣修复术(MVr),5.4%患

JACC:他汀类药物的使用与认知力下降不呈相关性

他汀类药物可能与记忆和认知力下降相关,本研究的目的旨在评估老年患者他汀类药物使用和记忆与认知力变化的相关性。本研究纳入分析了MAS研究中的1037名70-90岁的患者,经过6年时间的随访,发现相比于从未使用他汀类药物的患者,他汀类药物使用者的记忆和认知力无明显差异,观察期间他汀类药物的启动与减缓记忆衰退的速度有关。探索性分析发现,使用他汀类药物与心脏病和载脂蛋白Eε4携带者的特异性记忆测试表现减弱

盘点:JACC十一月第4期研究一览

1. 他汀类药物的使用与认知力下降不呈相关性DOI: 10.1016/j.jacc.2019.09.041http://www.onlinejacc.org/他汀类药物可能与记忆和认知力下降相关,本研究的目的旨在评估老年患者他汀类药物使用和记忆与认知力变化的相关性。本研究纳入分析了MAS研究中的1037名70-90岁的患者,经过6年时间的随访,发现相比于从未使用他汀类药物的患者,他汀类药物使用者的

Chest:COPD患者的心血管风险

由此可见,对未选择的原因不同的COPD患者分析表明:1)COPD本身不足以解释其增加aPWV,2)吸烟是COPD患者aPWV增加的危险因素。